| pubmed-article:9305603 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0023508 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C0031525 | lld:lifeskim |
| pubmed-article:9305603 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:9305603 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:9305603 | pubmed:dateCreated | 1997-10-16 | lld:pubmed |
| pubmed-article:9305603 | pubmed:abstractText | To substantiate the reported sensitivity of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) to St Jude-type multiagent chemotherapy and to identify means of selecting patients most likely to benefit from such treatment, we analyzed the clinical and biologic characteristics of 12 patients with classic Ph+ ALL who were treated in either of two total therapy programs at St Jude Children's Research Hospital (1989-1994). Event-free survival estimates for this cohort were compared with historical data on 11 patients from an earlier total therapy study (Lancet 1994; 343: 331-332). The prognostic importance of age, white blood cell count and other presenting features was assessed by the logrank test in all 23 patients. Complete remissions were induced in 92% of the patients treated since 1989, compared with 82% of the historical control group (P > 0.05). There was essentially no difference in event-free survival between the study group and historical controls (4-year Kaplan-Meier estimates, 33 +/- 19% s.e. vs 36 +/- 13%). Further analysis of potentially informative risk factors identified a good-prognosis subgroup defined by an initial white blood cell count of < or =25 x 10(9)/l and a 4-year event-free survival of 73 +/- 19%. In conclusion, intensive multiagent chemotherapy offers an attractive therapeutic option for children and adolescents with Ph+ ALL and low presenting leukocyte count. | lld:pubmed |
| pubmed-article:9305603 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305603 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305603 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9305603 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305603 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9305603 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9305603 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9305603 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:EvansW EWE | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:CristWW | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:RaimondiS CSC | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:RibeiroR CRC | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:PuiC HCH | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:RiveraG KGK | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:HancockM LML | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:SandlundJ TJT | lld:pubmed |
| pubmed-article:9305603 | pubmed:author | pubmed-author:BroniscerAA | lld:pubmed |
| pubmed-article:9305603 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9305603 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:9305603 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9305603 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9305603 | pubmed:pagination | 1493-6 | lld:pubmed |
| pubmed-article:9305603 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:meshHeading | pubmed-meshheading:9305603-... | lld:pubmed |
| pubmed-article:9305603 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9305603 | pubmed:articleTitle | Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. | lld:pubmed |
| pubmed-article:9305603 | pubmed:affiliation | Department of Hematology-Oncology, St Jude Children's Research Hospital, and the University of Tennessee, Memphis, College of Medicine, 38105, USA. | lld:pubmed |
| pubmed-article:9305603 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9305603 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9305603 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9305603 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9305603 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9305603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9305603 | lld:pubmed |
